Brickell is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases.

OUR RESEARCH

Pipeline
Our current pipeline consists of new molecular entities with relevant mechanisms of action in skin diseases, targeting significant market opportunities in the global dermatology market.

 

VIEW PIPELINE
Therapeutic Areas
Our current pipeline consists of new molecular entities targeting the treatment of the following indications:
  • Hyperhidrosis
  • Cutaneous T-cell Lymphoma
  • Psoriasis

 

LEARN MORE
Brickell Outward Bound Leadership Retreat 2018